Streetbeat News

Analyst Ratings

ASAN

Piper Sandler analyst Brent Bracelin has maintained an Underweight rating on Asana (NYSE:ASAN) but increased the price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:33 pm

ADBE

Piper Sandler analyst Brent Bracelin has maintained an Overweight rating on Adobe (NASDAQ:ADBE) and increased the price target from $650 to $705. This adjustment reflects a positive outlook on Adobe's stock performance.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:32 pm

CBZ

Sidoti & Co. analyst Marc Riddick has downgraded CBIZ (NYSE:CBZ) from Buy to Neutral and set a price target of $63. This change reflects a revised outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:18 pm

WLK

TPH Energy Research analyst Matthew Blair has upgraded Westlake (NYSE:WLK) from Sell to Hold, indicating a change in the firm's outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:15 pm

PROK

B of A Securities analyst Jason Gerberry downgraded ProKidney (NASDAQ:PROK) from Buy to Neutral and reduced the price target from $8 to $2.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:08 pm

AAN

Stephens & Co. analyst Vincent Caintic upgraded Aarons (NYSE:AAN) from Equal-Weight to Overweight, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:04 pm

AXP

Stephens & Co. analyst Vincent Caintic upgraded American Express (NYSE:AXP) from Underweight to Equal-Weight and set a price target of $193.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:02 pm

HRMY

Harmony Biosciences (NASDAQ:HRMY) has been evaluated by 6 analysts over the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is now $38.5, down 30.63% from the previous $55.50. Recent analyst actions include maintaining, raising, and lowering ratings and price targets. Harmony Biosciences is a commercial-stage pharmaceutical company with a focus on rare neurological diseases. Financially, the company has shown strong performance with a revenue growth rate of 36.74%, a net margin of 24.0%, an ROE of 7.96%, an ROA of 5.0%, and a low debt-to-equity ratio of 0.41.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 2:01 pm

NTST

Netstreit (NYSE:NTST) has been rated by 9 analysts in the past three months, with a mix of bullish to bearish sentiments. The average 12-month price target is $16.75, down 14.54% from the previous average. Analysts from firms like Wolfe Research, Exane BNP Paribas, and Keybanc have updated their ratings and price targets, reflecting changes in market dynamics and company performance. Netstreit, a REIT, has shown a revenue growth of 30.31% and a net margin of 13.29%, but its ROE and ROA are below industry averages. The company has a lower market cap and a conservative debt-to-equity ratio of 0.49.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 2:00 pm

NAVI

Navient (NASDAQ:NAVI) has received mixed analyst ratings over the last three months, with 5 indifferent and 2 somewhat bearish ratings. The average 12-month price target is $16.86, with a high of $18.00 and a low of $16.00, marking a 14.42% decrease from the previous average. Analysts from Stephens & Co., Jefferies, TD Cowen, Citigroup, and JP Morgan have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Navient's financials show strong revenue growth and net margin, but challenges in asset utilization and debt management.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 2:00 pm